Zobrazeno 1 - 10
of 20
pro vyhledávání: '"SaeHeum Song"'
Publikováno v:
Journal of Clinical Pharmacology
Olmesartan medoxomil is a selective angiotensin II receptor antagonist indicated for the treatment of hypertension.1 In the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP; ClinicalTrials.gov identifier: {"type":"clinical-tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb4fde3d7802972a954fef57e257ca4d
https://doi.org/10.1002/jcph.572
https://doi.org/10.1002/jcph.572
Publikováno v:
The Journal of Clinical Pharmacology. 54:910-916
Edoxaban is an oral, once-daily, direct factor Xa (FXa) inhibitor that has been evaluated for the prevention of stroke in patients with atrial fibrillation (AF) and for the treatment and prevention of venous thromboembolism (VTE) recurrence. Pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7028efebb013d487f5ae733d96cde5e
https://doi.org/10.1002/jcph.306
https://doi.org/10.1002/jcph.306
Autor:
Shashank Rohatagi, Helen Moore, Reinilde Heyrman, SaeHeum Song, Michelle Green, Raymond Miller, Timothy J. Carrothers, James Lee, Michael Melino, Daniel E. Salazar, Antonia Wang, Manini Patel
Publikováno v:
Clinical Pharmacology in Drug Development. 2:103-112
CS-8635, a fixed-dose triple combination of olmesartan, amlodipine, and hydrochlorothiazide, was developed to address the growing need for additional blood pressure (BP) reduction in patients not controlled with dual-combination therapies. Prior to P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b55fd7f812b63ff305ba02e447a5756
https://doi.org/10.1002/cpdd.17
https://doi.org/10.1002/cpdd.17
Autor:
Thomas G. Wells, Douglas L. Blowey, Reinilde Heyrman, Daniel E. Salazar, Janice E. Sullivan, Joseph R. Sherbotie, SaeHeum Song, Shashank Rohatagi, Jeffrey L. Blumer
Publikováno v:
Pediatric Drugs. 14:401-409
Background: The prevalence and importance of hypertension in younger patients is becoming increasingly recognized; however, only a limited number of clinical trials have been conducted in the pediatric population. Objective: The aim of this study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db304e5a23e5af1e64ec3c7a7759b50
https://doi.org/10.2165/11631450-000000000-00000
https://doi.org/10.2165/11631450-000000000-00000
Autor:
Robert P. Giugliano, Helen Kastrissios, Tomas S. Bocanegra, Simon Zhou, Michelle Green, Shashank Rohatagi, Indravadan Patel, Timothy J. Carrothers, Bruce E Dornseif, SaeHeum Song, Satoshi Kunitada, Minggao Shi, Jeanne Mendell, Daniel E. Salazar, Elliott M. Antman, Masaya Tachibana
Publikováno v:
Thrombosis and Haemostasis. 107:925-934
SummaryEdoxaban is a novel, orally available, highly specific direct inhibitor of factor Xa and is currently being developed for the treatment and prevention of venous thromboembolism and prevention of stroke and systemic embolism in patients with no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1257db9dae2118086028e4446bbb590
https://doi.org/10.1160/th11-08-0566
https://doi.org/10.1160/th11-08-0566
Autor:
D R Wada, Timothy J. Carrothers, Daniel E. Salazar, J Shi, Shashank Rohatagi, SaeHeum Song, Reinilde Heyrman
Publikováno v:
Clinical Pharmacology & Therapeutics. 91:250-256
Modeling and simulation were used extensively in the development of an indication for the use of olmesartan medoxomil in pediatric patients with hypertension. Simulations based on models developed in adult patients indicated that two dose groups were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a7c1aa45b4f0b3430391e237e569880
https://doi.org/10.1038/clpt.2011.220
https://doi.org/10.1038/clpt.2011.220
Publikováno v:
Clinical Cancer Research. 10:6058-6065
We reported induction of broad-spectrum chemoresistance by acidic and basic fibroblast growth factors and chemosensitization by their nonspecific inhibitor suramin at nontoxic and subtherapeutic doses. This study evaluated whether low-dose suramin en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75eddc8ffd451b1cd288a502cc659061
https://doi.org/10.1158/1078-0432.ccr-04-0595
https://doi.org/10.1158/1078-0432.ccr-04-0595
Autor:
Oleg Zernovak, Prasanna Kumar, Jarema Kochan, Joseph Rosenthal, Roohi Gajee, Rebecca L. Olin, Michael Rosen, Tharin Limsakun, Courtney D. DiNardo, Shuquan Chen, SaeHeum Song, Michael Andreeff
Publikováno v:
Blood. 128:593-593
Background:MDM2, a negative regulator of the tumor suppressor p53, is overexpressed in a number of cancers including hematological malignancies. Disrupting the MDM2-p53 interaction represents an attractive approach to treat cancers expressing wild-ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9df2bebd3ecf745cdf0186ab2aeff863
https://doi.org/10.1182/blood.v128.22.593.593
https://doi.org/10.1182/blood.v128.22.593.593
Autor:
Mrinal M. Gounder, Neeta Somaiah, David M. Hyman, Jarema Kochan, Prasanna Kumar, Michael Rosen, Funda Meric-Bernstam, Tyler Masters, Sugun Gokmen, Amy Weise, SaeHeum Song, Oleg Zernovak, Shuquan Chen, Patricia LoRusso, Roohi Gajee, David S. Hong, Todd M. Bauer, Gary K. Schwartz, Richard D. Carvajal
Publikováno v:
Journal of Clinical Oncology. 34:2581-2581
2581Background: About 50% of tumors harbor inactivating mutations in TP53. Aberrant MDM2 signaling is an alternate mechanism to inactivate wild type (WT) p53. In preclinical studies, DS-3032b disrupted the MDM2-WTp53 interaction resulting in cell cyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6db2eb886722622856bc80369fc441cc
https://doi.org/10.1200/jco.2016.34.15_suppl.2581
https://doi.org/10.1200/jco.2016.34.15_suppl.2581
Autor:
SaeHeum, Song, Timothy J, Carrothers, Helen, Moore, Michelle, Green, Raymond, Miller, Shashank, Rohatagi, James, Lee, Antonia, Wang, Michael, Melino, Manini, Patel, Reinilde, Heyrman, Daniel E, Salazar
Publikováno v:
Clinical pharmacology in drug development. 2(2)
CS-8635, a fixed-dose triple combination of olmesartan, amlodipine, and hydrochlorothiazide, was developed to address the growing need for additional blood pressure (BP) reduction in patients not controlled with dual-combination therapies. Prior to P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f228f42909fd278f9db9dbe55624ef2d
https://pubmed.ncbi.nlm.nih.gov/27121665
https://pubmed.ncbi.nlm.nih.gov/27121665